NCT01273207View on ClinicalTrials.gov

Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 2, 2012

Primary Completion Date

May 10, 2019

Study Completion Date

May 23, 2019

Conditions
Bronchiolitis ObliteransConstructive BronchiolitisGraft Versus Host DiseaseBronchiolitis, ExudativeBronchiolitis, ProliferativeGraft-Versus-Host Disease
Interventions
DRUG

Cyclosporine Inhalation Solution (CIS)

CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT01273207 - Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans | Biotech Hunter | Biotech Hunter